March 17 (Reuters) - Lantheus Holdings Inc LNTH.O:
LANTHEUS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR LNTH-2501 (GA 68 EDOTREOTIDE), A PET DIAGNOSTIC IMAGING KIT TARGETING SOMATOSTATIN RECEPTOR-POSITIVE (SSTR+) NEUROENDOCRINE TUMORS $(NETS)$
LANTHEUS HOLDINGS INC - STANDARD REVIEW EXTENSION FOR LNTH-2501 NOT RELATED TO EFFICACY OR SAFETY DATA
LANTHEUS HOLDINGS INC - FDA EXTENDS REVIEW OF LNTH-2501 NDA TO JUNE 29, 2026
LANTHEUS HOLDINGS INC - FDA EXTENDS PDUFA GOAL DATE FOR LNTH-2501 TO JUNE 29, 2026
Source text: ID:nGNXbZfXpL
Further company coverage: LNTH.O
((Reuters.Briefs@thomsonreuters.com;))